Shares of Amgen Inc. AMGN inched 0.19% higher to $264.49 Tuesday, on what proved to be an all-around positive trading session ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

Amgen's leukemia drug Blincyto infringes patents owned by Germany's Lindis Biotech, a Delaware federal jury said in a verdict ...

We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options ...

The most recent trading session ended with Amgen (AMGN) standing at $264, reflecting a +0.24% shift from the previouse trading day's closing. This move lagged the S&P 500's daily gain of 0.73%.

StockNews.com lowered shares of Amgen (NASDAQ:AMGN – Free Report) from a strong-buy rating to a buy rating in a research ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Novo Nordisk's CagriSema shows 22.7% weight loss in Phase 3 trials, while tolerability concerns grow. MariTide offers ...

Novo Nordisk stock crashed Friday after the firm's next-generation weight-loss drug missed expectations in a highly ...

Amgen, a biotechnology company, announced last week that it will invest $1 billion in expanding its manufacturing facility in ...

Amgen's (AMGN) once-monthly GLP-1, which experts expect to be a game changer in the weight-loss space, is showing continued promise as it advances in clinical trials. The company reported 20% ...

Amgen today is the biggest biotechnology company in the world, but its plush headquarters, global reach and tens of thousands of employees belie its humble origins. Founded in 1980 as Applied ...